Healthcare Technology for Providers Stocks Q3 Review: Evaluating Astrana Health (NASDAQ:ASTH)

Q3 Review: Healthcare Technology for Providers

As the third quarter earnings season concludes, let's examine which companies in the healthcare technology for providers sector stood out—both positively and negatively. This includes a close look at Astrana Health (NASDAQ:ASTH) and its industry peers.

Industry Overview

Healthcare technology firms supply software and analytics solutions that help hospitals and clinics operate more efficiently and enhance patient care, often leveraging value-based care models. The sector is poised for further expansion as providers increasingly embrace digital transformation to control costs and meet growing patient needs. Key drivers include the integration of artificial intelligence and government support for digital initiatives. However, the industry faces obstacles such as lengthy sales processes, hesitancy among providers to adopt new technologies, shrinking hospital budgets, and cybersecurity risks—all of which could hinder broader adoption.

Q3 Performance Snapshot

Among the four healthcare technology for providers companies we monitor, the group collectively delivered a solid third quarter. Revenue exceeded analyst expectations by 6.2%, although guidance for the next quarter was 0.7% below consensus forecasts.

Despite some companies outperforming others, the sector as a whole has seen share prices fall, with an average decline of 4.9% since the most recent earnings announcements.

Q3's Underperformer: Astrana Health (NASDAQ:ASTH)

Previously known as Apollo Medical Holdings until early 2024, Astrana Health operates a tech-enabled platform that empowers physicians to deliver coordinated care and participate in value-based payment programs.

For the quarter, Astrana Health reported $956 million in revenue—a 99.7% increase year-over-year—surpassing analyst projections by 0.6%. However, the company missed analyst expectations for both EPS and full-year revenue guidance, making it a challenging quarter despite the strong top-line growth.

Brandon Sim, President and CEO, commented, "Astrana delivered solid third quarter results and demonstrated strong momentum in our first quarter of combined operations with Prospect Health."

While Astrana Health posted the fastest revenue growth among its peers, it also fell shortest of analyst expectations. The market responded negatively, with shares dropping 6.4% since the report, currently trading at $22.35.

Curious if Astrana Health is a buy right now?

Q3's Top Performer: Privia Health (NASDAQ:PRVA)

Privia Health operates across 13 states and Washington, D.C., supporting over 4,300 providers who care for more than 4.8 million patients. The company leverages technology to help physicians enhance their practices, elevate patient experiences, and transition to value-based care.

In the third quarter, Privia Health generated $580.4 million in revenue, marking a 32.5% year-over-year increase and beating analyst estimates by 16.6%. The company also exceeded expectations for both EPS and revenue, delivering a standout quarter.

Despite these strong results, the market reaction was muted, with shares down 6.4% since the earnings release, now trading at $23.42.

Interested in a deeper dive on Privia Health?

Evolent Health (NYSE:EVH)

Founded in 2011, Evolent Health aims to transform care for patients with complex needs by offering specialty care management and technology solutions to health plans and providers.

Evolent Health reported $479.5 million in revenue, a 22.8% year-over-year decrease, but still surpassed analyst expectations by 2.6%. The quarter was challenging, with significant misses on EPS and EBITDA guidance for the next quarter.

Although Evolent Health raised its full-year guidance more than any peer, it experienced the slowest revenue growth in the group. Shares have plummeted 43.9% since the earnings release, now trading at $3.36.

Omnicell (NASDAQ:OMCL)

Omnicell is dedicated to realizing the vision of an "Autonomous Pharmacy"—a future with zero medication errors. The company provides automation and adherence solutions that help healthcare systems and pharmacies minimize mistakes and boost efficiency.

For the quarter, Omnicell posted $310.6 million in revenue, up 10% from the prior year and 5% above analyst expectations. The company also beat EPS and revenue estimates, marking a robust quarter.

Shares have surged 63.9% since the earnings announcement, with the stock now trading at $48.47.

Discover High-Quality Investment Opportunities

Looking to invest in companies with strong fundamentals? Explore our Hidden Gem Stocks and add them to your watchlist. These businesses are well-positioned for growth, regardless of market or political shifts.

The StockStory analyst team—comprised of experienced professional investors—leverages quantitative analysis and automation to deliver timely, high-quality market insights.